Willem Hassel - Amgen Independent Vice Chairman of the Supervisory Board
| AMG Stock | EUR 282.20 1.00 0.36% |
Chairman
Mr. Willem van Hassel was appointed Vice Chairman of the Supervisory Board of AMG Advanced Metallurgical Group N.V., effective as of May 2, 2018. He has served as Member of the Supervisory Board of the Company. He obtained his Law Degree at Erasmus University Rotterdam in 1964. Until 2000, for nearly 30 years, Mr. van Hassel has practised in various legal areas, amongst which company law in general, mergers and acquisitions, shareholders and board room disputes, reorganisations and bankruptcy cases, structuring of publicprivate partnerships and privatizations. During his legal career he has always combined his counseling activities with litigation, both in court cases and arbitration. He has acted as counsel to Dutch Parliament as well as the Dutch Accounting Office. In the early 1990s, he was president of the Netherlands Bar Association. During the last four years of his legal career he was chairman and managing partner of Trenit Van Doorne, at the time one of the Dutch leading law firms. Until 2000 he was also a Deputy Judge with the Rotterdam District Court. Furthermore Mr. van Hassel gets appointments by the Enterprise Chamber of the Court of Appeals in Amsterdam as an independent investigator temporary board member in mismanagement suits and shareholders deadlocks. In various capacities he is actively involved with the developments in the field of good governance. He is also editor of the Toolkit Commissariaat and serves and has served on various supervisory boards, including Eurocommercial Properties NV until recently. Mr. van Hassel furthermore served on the Board of the Foundation Continuity AMG until March 12th, 2017 when he resigned to prepare for his nomination for AMGs Supervisory Board. since 2018.
| Age | 73 |
| Tenure | 6 years |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Joaquin Duato | Johnson Johnson | 60 | |
| Alex Gorsky | Johnson Johnson | 63 | |
| Jennifer Taubert | Johnson Johnson | 59 | |
Management Performance
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, VP Officer | ||
| Robert Bradway, CEO Chairman | ||
| Peter Griffith, Ex CFO | ||
| Murdo Gordon, Ex Operations | ||
| Dagmar Bottenbruch, Independent Member of the Supervisory Board | ||
| Donatella Ceccarelli, Independent Member of the Supervisory Board | ||
| Nancy Grygiel, Sr Officer | ||
| Willem Hassel, Independent Vice Chairman of the Supervisory Board | ||
| Frank Lohner, Independent Member of the Supervisory Board | ||
| Herbert Depp, Independent Member of the Supervisory Board | ||
| Steve Hanke, Independent Chairman of the Supervisory Board | ||
| Jackson Dunckel, Member of the Management Board, Chief Financial Officer | ||
| Michele Fischer, Vice President IR Contact Officer | ||
| Esteban Santos, Ex Operations | ||
| Heinz Schimmelbusch, Chairman of the Management Board, Chief Executive Officer | ||
| Eric Jackson, Member of the Management Board and Presidentident of the AMG Processing Division, COO | ||
| Jonathan Graham, Gen VP | ||
| Mike Zahigian, VP Officer | ||
| David MD, Ex RD | ||
| Arvind Sood, VP Relations |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 163.09 B | |||
| Shares Outstanding | 533.98 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 79.91 % | |||
| Price To Earning | 17.42 X | |||
| Price To Book | 38.95 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Amgen Stock
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.